MK-677 Long-Term Results: What 2 Years of Trials Actually Show

MK-677 kept IGF-1 elevated for 24 months without a single sign that the receptor was tiring of it. That is the finding from the only two-year double-blind placebo-controlled human trial ever run on this compound. Most MK-677 content online recycles data from 4 to 12-week studies and stops where the interesting data begins. This article covers what the full long-term record actually shows, what it does not show, and what your genetics change about the math before you commit to a year-long protocol.

MK-677 is a pill that imitates the hunger hormone ghrelin. It docks into GHSR1a, the receptor ghrelin itself uses, and triggers the pituitary to release growth hormone in bursts. Unlike injected GH, it does not shut down your own production. Unlike ipamorelin or GHRP-2, you swallow it. Being both orally absorbed and driven by your own pituitary made it the most-studied non-injectable GH secretagogue in clinical research.

The long-term question has always been: does the effect hold, or does it fade the way hexarelin does in two weeks? The Nass data answers that. The Adunsky data, from a different 2011 trial, introduces a safety caveat that most review articles quietly omit. Both belong in your protocol decision.

What Happens in the First 90 Days of MK-677

The earliest human pharmacology data on MK-677 comes from Chapman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 1996. They administered 25 mg daily to healthy older adults and measured 24-hour GH profiles at baseline and after two months of treatment. Mean 24-hour GH rose 97% from baseline. The rise came from bigger bursts, not more of them. The natural rhythm stayed intact.

That distinction matters. MK-677 does not turn GH into a steady drip the way a continuous infusion does. It makes the body's own bursts larger. Most endocrinologists consider the burst pattern kinder to the receptor and better for the liver's ability to keep making IGF-1 without the response fading. The result: IGF-1 typically rises within 2 to 4 weeks of starting 25 mg daily, and most users notice improved sleep quality in the same window, driven by enhanced slow-wave sleep.

The first two to three weeks also bring fluid retention. This is a known GH-mediated effect. Kidneys express GH receptors, and higher GH signals them to retain sodium. Most users lose the extra fluid by week four as the kidneys adapt. Swelling that persists past a month is a signal to reduce dose. Running through it without addressing the underlying cause is how people end up with worsening fluid retention over longer cycles.

What the 12-Month Body Composition Data Actually Shows

The Nass 2008 trial measured body composition at 12 months with a DEXA scan, the X-ray-based method that separates fat, lean tissue and bone. The MK-677 group gained 1.1 kg of lean mass while the placebo group lost 0.5 kg. Net difference: 1.6 kg in favor of MK-677. Not transformative, but real, statistically significant, and directionally consistent with what GH axis activation produces in older adults who are not in a caloric surplus or structured resistance training program.

Here is the part most guides omit: muscle function did not improve. Handgrip strength, stair-climbing power, and walking speed did not differ between groups at 12 months. The lean mass gain appeared on the scale but not in functional performance metrics. The same split, more lean tissue but no more function, turns up repeatedly in injected GH trials in older adults. The implication for younger, active users is that MK-677 alone, without progressive resistance training, is unlikely to produce the strength and performance gains the forums describe. The studies that show meaningful functional gains pair the compound with training. Protocol design matters as much as the molecule.

Fat mass declined modestly in the MK-677 group. LDL cholesterol fell by approximately 0.14 mmol/L (about 5 mg/dL), a small but directionally consistent effect. Neither finding was the headline result, but both add to the picture of a compound with genuine if moderate metabolic effects at 12 months.

Does MK-677 Stop Working After a Few Months?

This is the question every long-term MK-677 user eventually asks. The answer from the only two-year RCT: no. At 25 mg/day, the receptor kept responding across the full two years. IGF-1 at month 24 was statistically equivalent to IGF-1 at month 1.

Compare that to hexarelin, the strongest injectable in the GHRP family. GH responsiveness starts fading within 7 to 14 days of daily hexarelin dosing. GHRP-2 fades meaningfully for most users within 8 to 12 weeks. MK-677, at standard oral doses, follows neither trajectory.

"Serum IGF-1 concentrations remained significantly elevated in the MK-677 group at the 24-month time point relative to placebo, with no statistically significant attenuation between the 12- and 24-month assessments, suggesting that the pituitary response to MK-677 was maintained without tachyphylaxis at the dose and duration studied."

Nass et al., Annals of Internal Medicine, 2008

Why MK-677 holds up at these doses is not fully settled. The leading explanation: because it makes the body's own bursts bigger rather than holding the receptor switched on all day, there are quiet windows between bursts in which the receptor recovers. Hexarelin and GHRP-2 at high doses keep the receptor occupied for longer and never allow that reset. MK-677's 5 to 6 hour half-life in the blood, taken once daily, seems to produce exactly the on-off pattern the receptor tolerates. This is the pharmacological argument for once-daily evening dosing rather than splitting into two smaller doses.

The Safety Signal Nobody Talks About

In 2011, Adunsky and colleagues published a multicenter Phase IIb trial in Archives of Gerontology and Geriatrics. They enrolled 123 elderly patients recovering from hip fracture (mean age approximately 80) and randomized them to 25 mg/day MK-677 or placebo for 24 weeks. The primary endpoint was functional recovery. The trial was terminated early by the safety monitoring board.

Congestive heart failure occurred in 6.5% of the MK-677 group versus 1.7% on placebo. That is roughly a 3.8-fold increase in one of the most serious cardiovascular events possible in a frail elderly population. The termination was warranted.

This result requires context before it produces panic. The Adunsky population was already at extremely high baseline cardiovascular risk: people in their eighties recovering from a hip fracture, most of them also carrying high blood pressure, chronic kidney disease, and a heart already working at its limit. The fluid retention MK-677 reliably produces in the first weeks could plausibly tip a heart that was just coping into failing. The Nass trial in a healthier elderly cohort did not show a cardiac signal.

That context does not make the signal disappear. The FDA cited the Adunsky cardiac findings in its December 2025 warning letters about ibutamoren-containing products. Anyone with existing heart failure, a heart that pumps out less blood per beat than it should, ongoing swelling, or significant high blood pressure should treat MK-677 as off the table, not merely as something to approach cautiously.

Why MK-677 and Insulin Resistance Are a Bad Pairing

Growth hormone pulls against insulin. It pushes the liver to release more glucose and makes muscle and fat less willing to take glucose up. That is why untreated acromegaly, the condition caused by a growth-hormone-secreting pituitary tumour, produces diabetes in a meaningful share of patients. MK-677 raises GH substantially, and the same consequences follow.

In the Nass 2008 trial, fasting glucose rose approximately 0.28 mmol/L (about 5 mg/dL) in the MK-677 group over 12 months, and insulin sensitivity fell in step, measured with HOMA-IR, a score calculated from your fasting glucose and insulin together. These are modest effects in a population that started metabolically normal. In someone who begins a cycle with fasting glucose already at 95 to 99 mg/dL, or with clinically elevated HOMA-IR, those modest effects can push the numbers out of the healthy range.

The practical protocol: run a fasting glucose and an HbA1c, your average blood sugar over the past three months, before you start. Recheck at 6 to 8 weeks. If you are already tracking bloodwork for IGF-1 timing, pull the full metabolic panel at the same draw. Catching a 10 mg/dL glucose creep at eight weeks is a fixable problem. Finding a prediabetes diagnosis a year into a cycle is not.

Bone Density: What the 18-Month Data Actually Found

The question of whether MK-677 protects bone is more complicated than the forums suggest. Murphy and colleagues ran an 18-month RCT in postmenopausal women with osteoporosis, published in the Journal of Clinical Endocrinology and Metabolism in 2001. They tested MK-677 alone, alendronate alone (the most common osteoporosis drug), and the combination.

MK-677 alone did not improve bone density at any site versus placebo over 18 months. It raised a marker of new bone being laid down by 22%, and a marker of old bone being broken down by 41%. Both sides of bone turnover sped up, and net density did not move because the two roughly cancelled. The combination arm with alendronate, which blocks the breakdown side while MK-677 drives the building side, did show a real gain at the hip: +4.2% versus +2.5% for alendronate alone.

The lesson for long-term MK-677 users: do not expect it to protect bone on its own. Both signals are real. Without a drug to hold the breakdown side down, the net effect on bone looks neutral over 18 months. For fracture risk, the combination approach with medical supervision is what the data supports.

What Happens to Your Gains When You Stop

No published RCT has prospectively characterized the MK-677 washout curve. The week-by-week IGF-1 decay after stopping has never been tracked in a controlled setting. What the pharmacology implies: MK-677 has a half-life in the blood of 5 to 6 hours, and levels fall away within 24 hours of the last dose. Because it works by prompting your own GH release rather than delivering GH or IGF-1 from outside, the natural burst pattern should return within days, not weeks.

Clinical expectation from the GH endocrinology literature is IGF-1 normalization within 1 to 2 weeks after stopping. The Nass 2008 crossover design provides indirect evidence: subjects who switched from MK-677 to placebo in year two showed reversal of lean mass gains and IGF-1 elevation. The direction is clear even though the timeline was not the study's focus.

The practical implication: the lean mass you build on MK-677 is not permanent without continuing the compound or maintaining the stimulus through training. The IGF-1 elevation is entirely cycle-dependent. Plan the off-period accordingly, and treat the 2-week washout window as the floor, not the ceiling, for how long recovery takes in a heavier user.

Why the Same Dose Lands So Differently on Different People

MK-677 varies more between individuals than anything else in its class. The same 25 mg can produce an IGF-1 of 180 ng/mL in one person and 340 ng/mL in another. Most of that spread is inherited, not behavioural.

The biggest single predictor is which growth hormone receptor you carry. It comes in a full-length form and a shorter one missing exon 3, written d3. In children treated with growth hormone, carriers of the short form grew 1.7 to 2 times faster, with roughly 30% more signal getting through. On a standard MK-677 dose, a carrier can push IGF-1 well above the reference range while feeling nothing that would warn them. The article on GHR exon 3 deletion and growth peptide response covers the mechanism and how to work out which group you are in before committing to a cycle.

The second variable is whether the receptor MK-677 acts on works properly in the first place. Variants that leave GHSR1a barely functional blunt the GH pulse from any ghrelin-imitating compound, MK-677 included. If ipamorelin or GHRP-2 did nothing for you at adequate doses, MK-677 uses the same door and will do the same nothing. Knowing that early is the difference between changing category and spending months on a protocol that was never going to work. For which GH peptides depend on that receptor and which go around it, the tesamorelin vs MK-677 vs CJC-1295 article has the breakdown.

Third is the carrier protein, IGFBP-3, which holds most circulating IGF-1 out of action until tissues call for it. Total IGF-1 is what comes back on a standard blood panel. What actually reaches your tissues is the unbound share, and that depends on how much carrier protein you make. Two people with the same total IGF-1 on MK-677 can get quite different muscle and recovery responses for that reason. If your bloodwork looks solid but results feel flat, look there before you raise the dose.

For where MK-677 fits in your protocol and how your DNA changes the ranking, see the MK-677 peptide profile. The genetic matching score on our report weighs all three of these in the same calculation.